Index · Artikel · Pfizer says on lookout for mid-size drug deals

Pfizer says on lookout for mid-size drug deals

2012-05-02 8
   
Advertisement
résumén">Pfizer Inc, which last week agreed to sell its baby formula business for almost $12 billion, is on the hunt for companies with promising new treatments for diabetes, cancer and neurological conditions, and willing to spend $4 billion or more ap
Advertisement

Pfizer says on lookout for mid-size drug deals


n">Pfizer Inc, which last week agreed to sell its baby formula business for almost $12 billion, is on the hunt for companies with promising new treatments for diabetes, cancer and neurological conditions, and willing to spend $4 billion or more apiece, company Chief Executive Ian Read said.

"I have no interest in a massive consolidating deal," Read said in an interview, referring to giant transactions like Pfizer's $67 billion purchase of rival U.S. drugmaker Wyeth in 2009, or its $60 billion merger with Pharmacia in 2003.

Read said Pfizer has an eye out for smaller "bolt-on" deals of roughly the same size as its $3.6 billion purchase of King Pharmaceuticals last year for its roster of pain medicines.

"That's not a hard number -- around that (amount) or a multiple of that if it was an attractive asset," Read said in an interview after Pfizer reported solid quarterly earnings despite generic competition that battered sales of its Lipitor cholesterol fighter.

King Pharma was the last major purchase by the global drugmaker. Its new search could help fuel a health-care industry buying spree that has seen four major deals announced in the last month. At least three more companies are said to be exploring a sale -- Amylin Pharmaceuticals, Human Genome Sciences Inc and Warner Chilcott Plc.

"We continue to see emerging markets as an opportunity area," Pfizer Chief Financial Officer Frank D'Amelio said, noting a profusion of recent deals that have beefed up the number of company medicines and consumer products in fast-growing South American and Asian markets.

Overseas demand accounted for 61 percent of Pfizer's first-quarter sales, up from 57 percent in the year-earlier quarter, with the increase due mainly to Lipitor's loss of U.S. patent protection in late November. The drug's global sales plunged 42 percent to $1.4 billion, with U.S. sales falling 71 percent during its first full quarter of exposure to generics.

But Pfizer's quarterly earnings topped Wall Street expectations as improved profit margins and strong sales of its Lyrica nerve-pain drug partly compensated for Lipitor's plunge.

"The story here is that Pfizer is dealing with its Lipitor patent loss surprisingly well," said Morningstar analyst Damien Conover. "When you lose the biggest medicine in the world and your earnings per share only fall 3 percent, that's a lot better than people expected a few years ago. Pfizer is mitigating the patent loss by cutting costs and bringing in good new drugs."

Shares of Pfizer were little changed in mid-afternoon trading on the New York Stock Exchange.

SQUEEZING GROWTH FROM OLDER DRUGS

Pfizer earned $1.79 billion, or 24 cents per share, in the first quarter. That compared with $2.2 billion, or 28 cents per share, a year earlier.

Excluding special charges to boost productivity and address legal matters, Pfizer earned 58 cents per share, from 60 cents a year ago. Analysts on average had expected 56 cents, according to Thomson Reuters I/B/E/S.

Total company revenue fell 7 percent to $15.41 billion, a bit below Wall Street expectations of $15.47 billion.

Citibank analyst Jon Boris said in a research note that U.S. pharmaceuticals sales of $5.19 billion were "solid," coming in about $290 million above his forecast. Overseas pharmaceuticals sales of $7.88 billion, down 1 percent from a year ago, were $230 million below his expectations.

Pfizer, whose research laboratories have produced few big-selling drugs in the past decade, is now eagerly awaiting U.S. approvals of two potential blockbuster treatments: blood clot preventer Eliquis and tofacitinib to treat rheumatoid arthritis.

In the meantime, it is squeezing good growth out of older medicines, including Lyrica, whose sales jumped 16 percent to $955 million in the quarter, fueled by growing demand in Japan.

Sales of painkiller Celebrex rose 7 percent to $634 million, while sales of arthritis treatment Enbrel rose 3 percent to $899 million. Premarin, its line of female hormone replacement drugs, topped forecasts, with sales rising 11 percent to $261 million.

But sales of its Prevnar vaccines against pneumonia and other infections fell 6 percent to $941 million due to fewer children getting booster shots during the period and a lower U.S. birth rate for eligible patients versus a year ago.

The New York-based drugmaker agreed last week to sell its baby formula business to Nestle SA for $11.85 billion to focus on its core pharmaceuticals business. On Tuesday, Pfizer said it planned to allocate proceeds from the deal to share repurchases and possibly other uses.

In the meantime, Pfizer said it still intends to decide this year whether to divest its animal health unit, with any separation of the business taking place between this July and July 2013. The unit's sales rose 4 percent in the quarter to $1.03 billion.

Should it part with the business, Pfizer has said it would probably be in the form of an initial public offering, a route that would avoid hefty taxes.

Pfizer, noting that it will consider its baby formula business a discontinued operation beginning in the second quarter, trimmed its full year-earnings forecast accordingly. It now expects earnings, excluding special items, of $2.14 to $2.24 per share, from its earlier view of $2.20 to $2.30 per share.

(Reporting by Ransdell Pierson in New York; Editing by Michele Gershberg, Lisa Von Ahn, Gunna Dickson)

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated

  • Was Zeitplan ist amtitriptyline?

    Welche Droge Zeitplan ist amtitriptyline auf? Ich wurde verhaftet, als ich anhielt und hatte eine amtitriptyline Pille auf der Bodenplatte von meinem Auto. Ich wurde mit Besitz einer kontrollierten Substanz aufgeladen und nicht eine kontrollierte Sub
  • 5 Cocktail Trends für ein neues Jahrzehnt

    5 Cocktail Trends für ein neues Jahrzehnt
    Foto von L. Marie / Flickr CC Wenn Handwerk Cocktails jemals Aszendent gewesen sind, hat es sich in der zweiten Hälfte des letzten Jahrzehnts gewesen. Cocktails aller Art waren in der Mode mit jedem mixologist / Barkeeper von hier nach Topeka eine We
  • Das Geheimnis des Ahornsirup Geruch

    Das Geheimnis des Ahornsirup Geruch
    Mr. T in DC / flickr Es begann alles im Fitnessstudio. Ich war Joggen auf dem Laufband, eine Meile in, wenn eine Wolke von Saccharin-süßen Duft mich überwältigt. Ich schaute nach links eine junge Co-ed mit Mascara-beschichteten Wimpern in einem rosa
  • Wenn Kagan Gespielt Doktor

    Wenn Kagan Gespielt Doktor
    Vor vierzehn Jahren an Präsident Clintons Position auf Teilweisgeburt Abtreibungen zu schützen, frisiert Elena Kagan eine Erklärung des American College of Frauenärzte. Konservative denke, das sie aus dem Supreme Court disqualifizieren sollte. Sie un
  • Sind schwere Krämpfe in den Beinen eine Nebenwirkung von Neurontin?

    Zum ersten Mal Gebrauch nahm von teh taub Empfindungen und Schmerzen des peripheren Neuropa dein weg, aber ich mehrere Angriffe von Bein und Fuß Krämpfe während dieser ersten Gebrauch Nacht erlebt. ----schneiden---- In der Antwort auf Rajive G ... be
  • Kann schizophrenen Patienten Tryptophan Ergänzungen zu nehmen?

    Mein Gärtner ist eine schizophrene und manchmal seine Medizin ausläuft, bevor er mehr in der örtlichen Klinik bekommt. Darf ich ihm seine Symptome Tryptophan zu beruhigen und zu reduzieren? ----schneiden---- In Antwort auf Marjorie ... bei 2011-01-27
  • ACHTUNG: Nehmen Sie nicht Armour Thyroid WENN SIE SCHWEIN allergisch reagieren !! Ich wurde am Armour Thyroid setzen durch meine

    ... Arzt vor etwa 2 Jahren, obwohl ich ihm mitgeteilt, dass ich mit einem Schwein Allergie diagnostiziert worden war. Ich wusste nicht, dass Armour Thyroid von Schweinen kam. Ich entwickelte einige sehr unangenehme Symptome wie tägliche Fieber (101-1
  • Early Stage Partners wirft $ 55M zweiten Fonds

    Early Stage Partners wirft $ 55M zweiten Fonds
    Venture Firma Early Stage Partners hat $ 55.000.000 für das zweite Fonds angehoben und erwartet , 40 Prozent seiner Investitionen in Life Sciences - Unternehmen zu gehen. Das Unternehmen schloss den Fonds kurz vor seiner erhofften für insgesamt $ 70
  • Concussions und kognitive Fähigkeiten: Welche Auswirkungen?

    Concussions und kognitive Fähigkeiten: Welche Auswirkungen?
    Eine Gehirnerschütterung ist eine traumatische Hirnverletzung, verursacht durch das Gehirn heftig Prellen oder im Inneren des Schädels verdrehen. Credit: Puwadol Jaturawutthichai | Shutterstock NEW YORK - Concussions dauerhafte und weitreichenden Fol
  • PSA ist fraglich, für die Bestätigung Prostata Cancer.Then was sind die Symptome?

    basierend auf dem Arzt für die Biopsie geraten? Ist es das Wachstum von Prostata führt Urometry, wenn die Behandlung mit Medikamenten, mit zu beginnen ist vorgeschrieben? Wenn Ihr Urinieren Frequenz auf die Hälfte fast reduziert hat, mit vergrößerten